What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Surgery, Chemotherapy, Ovarian cancer and Oncology.
His work in the fields of Internal medicine, such as Regimen and Maintenance therapy, overlaps with other areas such as Olaparib and PARP inhibitor.
His research in Surgery intersects with topics in Clinical trial and Hazard ratio.
His Temozolomide study in the realm of Chemotherapy connects with subjects such as Combretastatin A-4 phosphate.
His Ca 125 antigen study, which is part of a larger body of work in Ovarian cancer, is frequently linked to MEDLINE, bridging the gap between disciplines.
Within one scientific family, Gordon J. S. Rustin focuses on topics pertaining to Gynecology under Oncology, and may sometimes address concerns connected to Interim analysis.
His most cited work include:
- Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations (1452 citations)
- Carboplatin or cisplatin (1158 citations)
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. (1098 citations)
What are the main themes of his work throughout his whole career to date?
Gordon J. S. Rustin spends much of his time researching Internal medicine, Chemotherapy, Oncology, Surgery and Ovarian cancer.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Gynecology.
Gordon J. S. Rustin works mostly in the field of Chemotherapy, limiting it down to concerns involving Methotrexate and, occasionally, Trophoblastic Tumor and Prognostic variable.
The various areas that Gordon J. S. Rustin examines in his Oncology study include Combination chemotherapy, Interim analysis, Maintenance therapy and Disease.
His Surgery research integrates issues from Carcinoma and Hazard ratio.
His study in the field of Ca 125 antigen and Ovarian carcinoma also crosses realms of MEDLINE.
He most often published in these fields:
- Internal medicine (63.68%)
- Chemotherapy (50.00%)
- Oncology (39.15%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (63.68%)
- Oncology (39.15%)
- Ovarian cancer (27.36%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Ovarian cancer, Surgery and Olaparib.
His studies in Maintenance therapy, Chemotherapy, Bevacizumab, Hazard ratio and Carboplatin are all subfields of Internal medicine research.
His Chemotherapy study integrates concerns from other disciplines, such as Adjuvant chemotherapy, Regimen and Tolerability.
His Oncology research includes elements of Interim analysis, Gynecology, Disease and Carcinoma.
The Ovarian cancer study combines topics in areas such as Cediranib, Adverse effect, Tamoxifen and Quality of life.
Gordon J. S. Rustin has included themes like Gastroenterology and Cancer in his Surgery study.
Between 2011 and 2021, his most popular works were:
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. (1098 citations)
- Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial (865 citations)
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. (373 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Gordon J. S. Rustin focuses on Internal medicine, Ovarian cancer, Oncology, Olaparib and Surgery.
In general Internal medicine study, his work on Hazard ratio, Maintenance therapy, Survival rate and Clinical trial often relates to the realm of Placebo, thereby connecting several areas of interest.
His Ovarian cancer research includes themes of Bevacizumab, Vomiting and Gastroenterology.
His studies examine the connections between Oncology and genetics, as well as such issues in Carcinoma, with regards to Serous fluid, Targeted therapy, KRAS and Neuroblastoma RAS viral oncogene homolog.
His Surgery study frequently involves adjacent topics like Cancer.
His Regimen study which covers Tolerability that intersects with Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
